COSCIENS Biopharma Inc.
CSCINASDAQHealthcare
$2.72
+$0.00(+0.00%)
Market Cap$8572175
P/E Ratio—
52W High$4.6054
52W Low$1.75
COSCIENS Biopharma Inc. (CSCI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CSCI · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $13.78M | $7.14M | $14.57M | $13.49M | $11.86M |
| Cost of Revenue | $6.98M | $4.21M | $6.02M | $5.28M | $5.88M |
| Gross Profit | $6.80M | $2.94M | $8.56M | $8.21M | $5.98M |
| Gross Margin %(computed) | 49.33% | 41.13% | 58.72% | 60.87% | 50.41% |
| Operating Expenses | |||||
| R&D Expenses | $8.30M | $2.04M | $1.37M | $3.04M | $1.48M |
| G&A Expenses | $10.45M | $5.53M | $2.87M | $2.54M | $2.57M |
| Total Operating Expenses | $33.08M | $7.57M | $4.24M | $5.78M | $4.32M |
| Operating Income | ($18.28M) | ($4.63M) | $4.32M | ($10.96M) | $1.66M |
| Operating Margin %(computed) | -132.63% | -64.80% | 29.65% | -81.30% | 13.99% |
| Interest Income | $0.44M | $0.06M | $0.14M | $0.00M | $0.00M |
| Interest Expense | $0.13M | $0.14M | $0.14M | $0.03M | $0.99M |
| Income Before Tax | ($15.22M) | ($4.37M) | $4.53M | $2.59M | $1.46M |
| Income Tax Expense | $0.08M | ($0.89M) | $1.08M | ($0.05M) | $0.00M |
| Net Income | ($15.31M) | ($3.48M) | $3.45M | $2.64M | $1.46M |
| Net Margin %(computed) | -111.07% | -48.79% | 23.66% | 19.57% | 12.27% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.93 | $-1.89 | $2.54 | $1.33 | $0.85 |
| Wtd Avg Shares | 2.58M | 1.85M | 1.84M | 1.83M | 1.83M |
| EBITDA | ($13.49M) | ($2.79M) | $6.14M | $4.18M | $3.04M |
| EBITDA Margin %(computed) | -97.87% | -39.07% | 42.13% | 31.00% | 25.61% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more COSCIENS Biopharma Inc. data
About COSCIENS Biopharma Inc. (CSCI) Income Statement
COSCIENS Biopharma Inc. (CSCI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, CSCI reported revenue of $0.01B, gross profit of $0.01B (gross margin 49.33%), and net income of ($0.02B) — a net profit margin of -111.07%.
Frequently asked questions
CSCI · 4 questionsCOSCIENS Biopharma Inc. (CSCI) reported revenue of $0.01B for 2024, up 93.0% year-over-year.
CSCI revenueCSCI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09